BRPI0315735B8 - método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico - Google Patents

método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico

Info

Publication number
BRPI0315735B8
BRPI0315735B8 BRPI0315735A BR0315735A BRPI0315735B8 BR PI0315735 B8 BRPI0315735 B8 BR PI0315735B8 BR PI0315735 A BRPI0315735 A BR PI0315735A BR 0315735 A BR0315735 A BR 0315735A BR PI0315735 B8 BRPI0315735 B8 BR PI0315735B8
Authority
BR
Brazil
Prior art keywords
ngf
breast cancer
vitro diagnosis
testing
therapeutic use
Prior art date
Application number
BRPI0315735A
Other languages
English (en)
Other versions
BRPI0315735B1 (pt
BRPI0315735A8 (pt
BR0315735A (pt
Inventor
Ikram Elyazidi Belkoura
Adriaenssens Eric
Choquet-Kastylevsky Geneviève
Hondermarck Hubert
Dolle Laurent
Original Assignee
Biomerieux Sa
Univ Des Sciences Et Technologies De Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Sa, Univ Des Sciences Et Technologies De Lille filed Critical Biomerieux Sa
Publication of BR0315735A publication Critical patent/BR0315735A/pt
Publication of BRPI0315735A8 publication Critical patent/BRPI0315735A8/pt
Publication of BRPI0315735B1 publication Critical patent/BRPI0315735B1/pt
Publication of BRPI0315735B8 publication Critical patent/BRPI0315735B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/48Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

método para o ensaio de ngf para a diagnose in vitro de câncer de mama e uso terapêutico. a presente invenção refere-se a um método para a diagnose in vitro de câncer de mama, o qual consiste em determinar a presença de ngf em uma amostra biológica derivada de um paciente suspeito de sofrer de câncer de mama. o dito método pode ser usado tanto em diagnose precoce, exame, acompanhamento terapêutico e prognóstico, quanto na diagnose de recorrência no caso de câncer de mama. a presente invenção também diz respeito ao uso de um par para ligação ao ngf ou de um inibidor do ngf para preparar um produto medicinal, o dito produto medicinal sendo, em particular, útil para bloquear a proliferação do tumor e a disseminação distante em pacientes sofrendo de câncer de mama. aplicações: diagnose e terapia.
BRPI0315735A 2002-10-28 2003-10-28 método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico BRPI0315735B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0213428A FR2846426B1 (fr) 2002-10-28 2002-10-28 Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
PCT/FR2003/003193 WO2004040312A2 (fr) 2002-10-28 2003-10-28 Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie

Publications (4)

Publication Number Publication Date
BR0315735A BR0315735A (pt) 2005-09-06
BRPI0315735A8 BRPI0315735A8 (pt) 2018-09-18
BRPI0315735B1 BRPI0315735B1 (pt) 2018-10-30
BRPI0315735B8 true BRPI0315735B8 (pt) 2021-05-25

Family

ID=32088308

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0315735A BRPI0315735B8 (pt) 2002-10-28 2003-10-28 método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico

Country Status (10)

Country Link
US (1) US7618790B2 (pt)
EP (2) EP2085783A1 (pt)
JP (1) JP4619125B2 (pt)
AT (1) ATE426813T1 (pt)
AU (1) AU2003285472B2 (pt)
BR (1) BRPI0315735B8 (pt)
DE (1) DE60326871D1 (pt)
ES (1) ES2324818T3 (pt)
FR (1) FR2846426B1 (pt)
WO (1) WO2004040312A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4587281B2 (ja) * 2004-06-21 2010-11-24 則男 長尾 癌転移抑制能測定する方法およびその測定器
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
KR20110053945A (ko) * 2008-06-05 2011-05-24 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 중합체 기능성 진화를 합성 동안 모니터하기 위한 방법 및 장치
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
JP7467866B2 (ja) * 2019-10-02 2024-04-16 住友ゴム工業株式会社 親水性基材及び親水性基材作製方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607507B1 (fr) 1986-12-02 1990-04-13 Centre Nat Rech Scient Nouveaux derives a-d-oligonucleotides, leur preparation et leur emploi
JPH08506654A (ja) * 1992-09-11 1996-07-16 セファロン,インコーポレイテッド 前立腺疾病の検出方法および治療方法
FR2710075B1 (fr) 1993-09-15 1995-10-27 Bio Merieux Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal.
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
CN1153064C (zh) * 1996-04-05 2004-06-09 约翰斯·霍普金斯大学 富集稀少细胞的方法
US20030104364A1 (en) * 1997-06-25 2003-06-05 Patricia A. Billing-Medel Reagents and methods useful for detecting diseases of the breast
US6008003A (en) * 1997-10-28 1999-12-28 Promega Corporation Non-invasive diagnostic method for interstitial cystitis and bladder cancer
FR2781802B1 (fr) 1998-07-31 2001-05-11 Bio Merieux Derives satures ou insatures de l'abietane, conjugues derives et utilisations dans une composition diagnostique, un reactif et un dispositif
IL151448A0 (en) * 2000-02-25 2003-04-10 Oxford Glycosciences Uk Ltd Proteins
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
AU2003242815A1 (en) 2002-03-13 2003-09-22 Biomerieux Method for the characterisation of circulating tumour cells stemming from solid cancers

Also Published As

Publication number Publication date
FR2846426A1 (fr) 2004-04-30
WO2004040312A2 (fr) 2004-05-13
DE60326871D1 (de) 2009-05-07
AU2003285472A1 (en) 2004-05-25
FR2846426B1 (fr) 2004-12-10
ES2324818T3 (es) 2009-08-17
BRPI0315735B1 (pt) 2018-10-30
WO2004040312A3 (fr) 2004-06-17
BRPI0315735A8 (pt) 2018-09-18
EP2085783A1 (fr) 2009-08-05
JP4619125B2 (ja) 2011-01-26
EP1556699B1 (fr) 2009-03-25
AU2003285472B2 (en) 2009-10-08
JP2006504101A (ja) 2006-02-02
BR0315735A (pt) 2005-09-06
EP1556699A2 (fr) 2005-07-27
US20060051818A1 (en) 2006-03-09
ATE426813T1 (de) 2009-04-15
US7618790B2 (en) 2009-11-17

Similar Documents

Publication Publication Date Title
HK1090093A1 (en) Method of selecting patients suitable for wt1 vaccine
BRPI0315735B8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
RU2013145524A (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона
CY1109557T1 (el) ΠΡΟΣΔΙΟΡΙΣΜΟΣ ΑΝΙΧΝΕΥΣΗΣ ΓΟΝΙΔΙΟΥ ΓΙΑ ΒΕΛΤΙΩΣΗ ΤΗΣ ΠΙΘΑΝΟΤΗΤΑΣ ΑΠΟΤΕΛΕΣΜΑΤΙΚΗΣ ΑΠΟΚΡΙΣΗΣ ΣΕ ΚΑΡΚΙΝΙΚΗ ΘΕΡΑΠΕΙΑ ΑΝΤΑΓΩΝΙΣΤΗ ErbB
PT1259248E (pt) Metodos para tratar, rastrear e detectar cancros que expressam o factor de crescimento vascular endotelial d
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
NO994932L (no) Blandinger og fremgangsmåter for behandling og diagnose av brystkreft
EP1744162A4 (en) Cancer diagnosis and treatment using an anti-ROBO1 antibody
Leontieva et al. Gerosuppression in confluent cells
Wu et al. Photodynamic effects on nasopharyngeal carcinoma (NPC) cells with 5-aminolevulinic acid or its hexyl ester
Kok et al. Induction of apoptosis on carcinoma cells by two synthetic cantharidin analogues
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
EP1600513A4 (en) METHOD FOR STUDYING A CELL
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
WO2023004083A3 (en) Compositions and methods for detection of bile duct cancer
BR0009573A (pt) Composições e métodos para o tratamento e diagnose do câncer de mama
WO2023004079A3 (en) Compositions and methods for detection of liver cancer
AR056831A1 (es) Metodo para el diagnostico y tratamiento de enfermedades cardiovasculares
Koechli et al. Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures
TW200632319A (en) Ex vivo cancer diagnostic method
DE602005024690D1 (de) Verfahren und verbindungen zum nachweis von medizinischen erkrankungen
Johnson et al. Targeting autotaxin to suppress stromal signaling in the tumor microenvironment to improve outcome to therapy in fibrotic tumor types
RU2789099C2 (ru) Способ определения снижения радиационно-индуцированной миграции клеток рака молочной железы человека линии MCF-7
US11975072B2 (en) Pyropheophorbide conjugate and use thereof in the treatment of cancer and as a fluorescent marker
Zhang et al. Neutrophil elastase specific fluorescent probe for early diagnosis of thyroiditis via serum sample testing and fluorescence imaging

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.